{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:45:08Z","timestamp":1791402308605,"version":"4.3.3"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,2,1]]},"DOI":"10.1093\/jac\/dki440","type":"journal-article","created":{"date-parts":[[2005,12,8]],"date-time":"2005-12-08T20:53:31Z","timestamp":1134075211000},"page":"317-325","source":"Crossref","is-referenced-by-count":87,"title":["An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia"],"prefix":"10.1093","volume":"57","author":[{"given":"Axel","family":"Glasmacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Ullmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Wedding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinrich","family":"Bodenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Wandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Boewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Pasold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Heinrich","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried","family":"D\u00f6lken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Junghanss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Andreesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Bertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,12,8]]},"reference":[{"key":"key\n\t\t\t\t20171010182143_B1","doi-asserted-by":"crossref","unstructured":"Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol2000; 110: 273\u201384.","DOI":"10.1046\/j.1365-2141.2000.02014.x"},{"key":"key\n\t\t\t\t20171010182143_B2","doi-asserted-by":"crossref","unstructured":"Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis2001; 32: 358\u201366.","DOI":"10.1086\/318483"},{"key":"key\n\t\t\t\t20171010182143_B3","doi-asserted-by":"crossref","unstructured":"Viscoli C, Girmenia C, Marinus A et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis1999; 28: 1071\u20139.","DOI":"10.1086\/514731"},{"key":"key\n\t\t\t\t20171010182143_B4","doi-asserted-by":"crossref","unstructured":"Marr KA, Seidel K, White TC et al. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis2000; 181: 309\u201316.","DOI":"10.1086\/315193"},{"key":"key\n\t\t\t\t20171010182143_B5","doi-asserted-by":"crossref","unstructured":"Maertens J, van Eldere J, Verhaegen J et al. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis2002; 186: 1297\u2013306.","DOI":"10.1086\/343804"},{"key":"key\n\t\t\t\t20171010182143_B6","doi-asserted-by":"crossref","unstructured":"Caillot D, Casasnovas O, Bernard A et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol1997; 15: 139\u201347.","DOI":"10.1200\/JCO.1997.15.1.139"},{"key":"key\n\t\t\t\t20171010182143_B7","doi-asserted-by":"crossref","unstructured":"Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis2002; 34: 7\u201314.","DOI":"10.1086\/323335"},{"key":"key\n\t\t\t\t20171010182143_B8","doi-asserted-by":"crossref","unstructured":"Link H, Bohme A, Cornely OA et al. Antimicrobial therapy of unexplained fever in neutropenic patients\u2014guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol2003; 82 Suppl 2: S105\u2013S117.","DOI":"10.1007\/s00277-003-0764-4"},{"key":"key\n\t\t\t\t20171010182143_B9","doi-asserted-by":"crossref","unstructured":"McLintock LA, Jordanides NE, Allan EK et al. The use of a risk group stratification in the management of invasive fungal infection: a prospective validation. Br J Haematol2004; 124: 403\u20134.","DOI":"10.1046\/j.1365-2141.2003.04794.x"},{"key":"key\n\t\t\t\t20171010182143_B10","doi-asserted-by":"crossref","unstructured":"Glasmacher A, Prentice AG, Gorschluter M et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for haematological malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol2003; 21: 4615\u201326.","DOI":"10.1200\/JCO.2003.04.052"},{"key":"key\n\t\t\t\t20171010182143_B11","unstructured":"Annaloro C, Oriani A, Tagliaferri E et al. Efficacy of different prophylactic antifungal regimens in bone marrow transplantation. Haematologica1995; 80: 512\u20137."},{"key":"key\n\t\t\t\t20171010182143_B12","doi-asserted-by":"crossref","unstructured":"Huijgens PC, Simoons-Smit AM, van Loenen AC et al. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. J Clin Pathol1999; 52: 376\u201380.","DOI":"10.1136\/jcp.52.5.376"},{"key":"key\n\t\t\t\t20171010182143_B13","doi-asserted-by":"crossref","unstructured":"Morgenstern GR, Prentice AG, Prentice HG et al. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol1999; 105: 901\u201311.","DOI":"10.1046\/j.1365-2141.1999.01465.x"},{"key":"key\n\t\t\t\t20171010182143_B14","doi-asserted-by":"crossref","unstructured":"Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med2003; 138: 705\u201313.","DOI":"10.7326\/0003-4819-138-9-200305060-00006"},{"key":"key\n\t\t\t\t20171010182143_B15","doi-asserted-by":"crossref","unstructured":"Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood2004; 103: 1527\u201333.","DOI":"10.1182\/blood-2003-08-2644"},{"key":"key\n\t\t\t\t20171010182143_B16","doi-asserted-by":"crossref","unstructured":"Glasmacher A, Prentice AG. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies. J Antimicrob Chemother2005; 56 Suppl S1: i23\u201332.","DOI":"10.1093\/jac\/dki221"},{"key":"key\n\t\t\t\t20171010182143_B17","doi-asserted-by":"crossref","unstructured":"Vreugdenhil G, Van Dijke BJ, Donnelly JP et al. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymphoma1993; 11: 353\u20138.","DOI":"10.3109\/10428199309067926"},{"key":"key\n\t\t\t\t20171010182143_B18","doi-asserted-by":"crossref","unstructured":"Harousseau JL, Dekker A, Stamatoullas-Bastard A et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother2000; 44: 1887\u201393.","DOI":"10.1128\/AAC.44.7.1887-1893.2000"},{"key":"key\n\t\t\t\t20171010182143_B19","doi-asserted-by":"crossref","unstructured":"Menichetti F, Del Favero A, Martino P et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis1999; 28: 250\u20135.","DOI":"10.1086\/515129"},{"key":"key\n\t\t\t\t20171010182143_B20","doi-asserted-by":"crossref","unstructured":"Nucci M, Biasoli I, Akiti T et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis2000; 30: 300\u20135.","DOI":"10.1086\/313654"},{"key":"key\n\t\t\t\t20171010182143_B21","doi-asserted-by":"crossref","unstructured":"Kaptan K, Ural AU, Cetin T et al. Itraconazole is not effective for the prophylaxis of fungal infections in patients with neutropenia. J Infect Chemother2003; 9: 40\u20135.","DOI":"10.1007\/s10156-002-0207-5"},{"key":"key\n\t\t\t\t20171010182143_B22","doi-asserted-by":"crossref","unstructured":"Bow EJ, Laverdiere M, Lussier N et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer2002; 94: 3230\u201346.","DOI":"10.1002\/cncr.10610"},{"key":"key\n\t\t\t\t20171010182143_B23","doi-asserted-by":"crossref","unstructured":"Kamaluddin M, McNally P, Breatnach F et al. Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Paediatr2001; 90: 1204\u20137.","DOI":"10.1111\/j.1651-2227.2001.tb03257.x"},{"key":"key\n\t\t\t\t20171010182143_B24","doi-asserted-by":"crossref","unstructured":"B\u00f6hme A, Ganser A, Hoelzer D. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol1995; 71: 311\u20132.","DOI":"10.1007\/BF01697985"},{"key":"key\n\t\t\t\t20171010182143_B25","doi-asserted-by":"crossref","unstructured":"Gillies J, Hung KA, Fitzsimons E et al. Severe vincristine toxicity in combination with itraconazole. Clin Lab Haematol1998; 20: 123\u20134.","DOI":"10.1046\/j.1365-2257.1998.00103.x"},{"key":"key\n\t\t\t\t20171010182143_B26","doi-asserted-by":"crossref","unstructured":"Marr KA, Leisenring W, Crippa F et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood2004; 103: 1557\u20139.","DOI":"10.1182\/blood-2003-07-2512"},{"key":"key\n\t\t\t\t20171010182143_B27","doi-asserted-by":"crossref","unstructured":"Colburn DE, Giles FJ, Oladovich D et al. In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology2004; 9: 217\u201321.","DOI":"10.1080\/10245330410001701585"},{"key":"key\n\t\t\t\t20171010182143_B28","doi-asserted-by":"crossref","unstructured":"Nucci M, Biasoli I, Akiti T et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis2000; 30: 300\u20135.","DOI":"10.1086\/313654"},{"key":"key\n\t\t\t\t20171010182143_B29","doi-asserted-by":"crossref","unstructured":"Boogaerts M, Maertens J, van Hoof A et al. Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. J Antimicrob Chemother2001; 48: 97\u2013103.","DOI":"10.1093\/jac\/48.1.97"},{"key":"key\n\t\t\t\t20171010182143_B30","doi-asserted-by":"crossref","unstructured":"Marr KA, Leisenring W, Crippa F et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood2004; 103: 1557\u20139.","DOI":"10.1182\/blood-2003-07-2512"},{"key":"key\n\t\t\t\t20171010182143_B31","unstructured":"Buggia I, Zecca M, Alessandrino EP et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res1996; 16: 2083\u20138."},{"key":"key\n\t\t\t\t20171010182143_B32","doi-asserted-by":"crossref","unstructured":"Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother2005; 56 Suppl S1: i17\u201322.","DOI":"10.1093\/jac\/dki220"},{"key":"key\n\t\t\t\t20171010182143_B33","doi-asserted-by":"crossref","unstructured":"Prentice AG, Warnock DW, Johnson SA et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. J Antimicrob Chemother1995; 36: 657\u201363.","DOI":"10.1093\/jac\/36.4.657"},{"key":"key\n\t\t\t\t20171010182143_B34","doi-asserted-by":"crossref","unstructured":"Prentice AG, Warnock DW, Johnson SA et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother1994; 34: 247\u201352.","DOI":"10.1093\/jac\/34.2.247"},{"key":"key\n\t\t\t\t20171010182143_B35","doi-asserted-by":"crossref","unstructured":"Glasmacher A, Hahn C, Molitor E et al. Itraconazole trough levels in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-cyclodextrin oral solution or coated-pellet capsules. Mycoses1999; 42: 591\u2013600.","DOI":"10.1046\/j.1439-0507.1999.00518.x"},{"key":"key\n\t\t\t\t20171010182143_B36","doi-asserted-by":"crossref","unstructured":"Glasmacher A, Hahn C, Leutner C et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses1999; 42: 443\u201351.","DOI":"10.1046\/j.1439-0507.1999.00505.x"},{"key":"key\n\t\t\t\t20171010182143_B37","unstructured":"Glasmacher A, Hahn C, Molitor E et al. Minimal effective trough concentrations for antifungal prophylaxis with itraconazole: a case\u2013control study. In: Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract M-890, p. 393. American Society for Microbiology, Washington, DC, USA."},{"key":"key\n\t\t\t\t20171010182143_B38","doi-asserted-by":"crossref","unstructured":"Boogaerts M, Winston DJ, Bow EJ et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med2001; 135: 412\u201322.","DOI":"10.7326\/0003-4819-135-6-200109180-00010"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/57\/2\/317\/2407659\/dki440.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T20:13:23Z","timestamp":1554840803000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/57\/2\/317\/804608\/An-openlabel-randomized-trial-comparing"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,8]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2005,12,8]]},"published-print":{"date-parts":[[2006,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dki440","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,2]]},"published":{"date-parts":[[2005,12,8]]}}}